FDA Advisory Panel Weighs Access to 7 Popular Peptides This Week

The FDA's Pharmacy Compounding Advisory Committee (PCAC) is meeting July 23-24 to evaluate whether 7 popular but unapproved peptides should be added to the agency's 503A Bulks List, a designation that, if finalized by FDA through rulemaking, would permit eligible state-licensed 503A compounding pharmacies to compound the substances for individually identified patients pursuant to valid prescriptions.^1,2 The meeting was formally announced through the Federal Register, opening the process to public comment and stakeholder testimony.³